Actively Recruiting
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
Led by Peng Zhang · Updated on 2023-11-28
30
Participants Needed
1
Research Sites
164 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis
CONDITIONS
Official Title
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 and above
- Diagnosed with SJS/TEN according to the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria
- Liver and kidney function is within acceptable ranges
- Blood tests including complete blood count, coagulation, and platelet count are within acceptable ranges
- Signed informed consent form
- Able to participate in follow-up visits and treatment plans
You will not qualify if you...
- Allergy to JAK inhibitors
- Pregnant or breastfeeding women
- Severe infections
- History of central nervous system demyelinating diseases
- History of lymphoproliferative diseases
- Active or latent tuberculosis
- HIV with CD4+ T cell count below 200/mL
- Active hepatitis B or C infection
- Blood clotting disorders or tendency for thrombosis
- Significant abnormalities in blood routine tests
- Liver or kidney dysfunction
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Dermatology, the First Affiliated Hospital of Fujian Medical University.
Fuzhou, Fujian, China, 350000
Actively Recruiting
Research Team
C
Chao Ji
CONTACT
P
Peng Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here